Facebook Twitter
Now With Over 23,000 Reviews!
Sign up now

Chart of Day: UPS Begins to Bounce

Feb 14, 2017

Sometimes, opportunity can be found in absolute disaster.

In December 2016, we called for UPS downside and watched it crater not long after on poor earnings and a predictable drop. Not long after, the stock became insanely oversold technically. So, on February 3, we recommended buying to open the April 105 call.

At the time, it traded at just $3.30. It’s now up to $4.35 as of yesterday. The stock is just beginning to rebound from oversold technicals and could eventually refill a bearish gap around $117 with patience.

 

 

Chart of Day: Easy Money with Bristol Myers

Feb 12, 2017

It shouldn't be this easy to make money.  

But if you follow the rules of technical, fundamental, news and billionaire trading, it becomes easier.

Ever since BMY plummeted on earnings and guidance, it became the buying opportunity of a lifetime. Far too much doom and gloom was priced in. It was time to buy the blood in the streets, as Rothschild often did. It was time to buy the excessive pessimism that Templeton did. And it was time to get greedy, as others got fearful, as Buffett still does.

As we noted on January 22, 2017:

Shares of Bristol Myers (BMY) took a bad hit the other day, falling from $60 to $49.23. However, it seems to have caught prior support at October 2016 lows. As long as that holds, the stock could bounce shortly from oversold MACD, RSI and Money Flow points, as well. Apparently, one of the company’s many drugs had bad news. But remember, this is BMY. It’s an industry heavyweight. It’s simply down temporarily, in our opinion. And we’re trying to take full advantage of that. Consider buying to open the March 2017 49 calls at market. BMY is far too oversold.

As of that Monday, January 23, the March 49 calls traded at $2.35. Then, on the evening of February 5, 2017, we reiterated buying the BMY March 49 calls, which traded at $2.80 by February 6. The calls now trade at $3.50, where we’re recommending that you sell to close half of each.

 

 

 

 

Chart of Day: ACADIA could be Bought Out

Feb 08, 2017

ACADIA (ACAD) is a stock that we’ve dipped in and out of a few times.

Now, with excitement surrounding potential sales, there are rumors it could be on the buyout target list. In fact, right now, there’s word that AstraZeneca, or even Pfizer may be interested in making an offer.  That’s because of two key, multi-billion dollar catalysts.

For one, ACADIA’s Parkinson’s disease Psychosis (PDP) treatment, Nuplazid, is the only drug on market approved to treat PDP and could help millions with $10 billion potential sales. The drug already produced $5.2 million in sales in its first quarter on shelves. 

It’s now also testing the drug with Alzheimer’s psychosis with incredible success, as well.

When tested with Alzheimer’s, the drug met its main goal in a mid-stage study.  It showed a statistically significant reduction in psychosis with a 3.76-point improvement after six weeks, as compared to 1.93-weeks with placebo.

There are two ways to trade the opportunity. One is to buy the stock at market prices. And, or two buy to open the ACAD June 2017 39 calls at market.

 

 

Chart of Day: And Boom goes CENX

Feb 07, 2017

On December 20, 2016, we spoke about the potential of Century Aluminum (CENX) at just $8.55 a share. It’s now up to $16.24 and running. In fact, if all goes according to plan it could test a high of $24 near-term. All thanks to an incredible rally in aluminum prices. Were you part of the trade? We want to hear about it.

Chart of Day: Bristol Myers Begins to Bounce

Feb 05, 2017

On January 22, 2017, we noted:

Shares of Bristol Myers (BMY) took a bad hit the other day, falling from $60 to $49.23. However, it seems to have caught prior support at October 2016 lows. As long as that holds, the stock could bounce shortly from oversold MACD, RSI and Money Flow points, as well. Apparently, one of the company’s many drugs had bad news. But remember, this is BMY. It’s an industry heavyweight. It’s simply down temporarily, in our opinion. And we’re trying to take full advantage of that. Consider buying to open the March 2017 49 calls at market. BMY is far too oversold.

As of that Monday, January 23, the March 49 calls traded at $2.35. They’re now up to $2.78 and running, as the underlying stock begins to rally well off recent lows.

Helping a bit, the FDA just approved its Opdivo drug for bladder cancer, giving it greater exposure to a $646.7 million bladder cancer market. The run in BMY is far from over in our opinion, though. In fact, if you have not taken a position, consider still buying the BMY March 49 calls at market prices.

Page:   2 ...